The current treatment options of transthyretin amyloidosis majorly revolve around relieving patients from symptoms associated with the condition, and treating the underlying cause with a liver transplant. Drugs such as Tafamidis (not approved in the U.S.) and Diflunisal, help in stabilizing the transthyretin tetramer and are majorly used in the treatment of familial amyloid polyneuropathy (FAP). Tafamidis (manufactured by Pfizer, Inc.) is currently in the phase 3 clinical trials in the U.S. Supporting therapies include treatments for heart diseases associated with cardiomyopathy as well as for neuropathy, depending on the severity of the symptoms
Diagnosis of transthyretin amyloidosis is carried out in various ways such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as NT-proBNP (N-terminal fragment of brain natriuretic peptide) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for disease diagnosis. In case of diagnosis of familial transthyretin amyloidosis, genetic testing for transthyretin gene mutations is carried out.
Market Dynamics
Absence of the U.S. Food & Drug Administration (FDA) approved therapies for transthyretin amyloidosis is expected to be a major factor responsible for growth of drugs in the pipeline such as Patisiran and Inotersen (expected to receive approval in 2018). The market is expected to exhibit exponential growth, owing to rapid uptake of approved therapies.
Various other drugs in the pipeline besides Patisiran and Inotersen, such as Tafamidis and ALN-TTRsc02 are expected to boost growth of the market in the near future. These therapies in the pipeline are meant to treat the underlying cause of the disease, which is expected to be a major factor for the previously untreated disease that lacks availability of robust therapy.
Key features of the study:
This report provides in-depth analysis of the U.S. transthyretin amyloidosis treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026)
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the U.S. transthyretin amyloidosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The U.S. transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the transthyretin amyloidosis treatment market
Detailed Segmentation:
U.S. Transthyretin Amyloidosis Treatment Market, By Drug:
Tafamidis
Diflunisal
Patisiran
Inotersen
Others
U.S. Transthyretin Amyloidosis Treatment Market, By Disease Type:
Hereditary Transthyretin Amyloidosis
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis
U.S. Transthyretin Amyloidosis Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Alnylam Pharmaceuticals, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Pfizer, Inc.
Prothena Corporation Plc
Teva Pharmaceutical Industries Ltd.
Becton, Dickinson, and Company
Fresenius Kabi AG
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug
o Market Snippet, By Disease Type
o Market Snippet, By Distribution Channel
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Clinical Characteristics
o Disease Diagnosis
o Epidemiology
o Transthyretin Amyloidosis Treatment Overview
o PEST Analysis
o PORTER's Analysis
o Therapy Study (Mechanism of Action)
4. U.S. Transthyretin Amyloidosis Treatment Market, By Drug, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Tafamidis
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Diflunisal
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Patisiran
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Inotersen
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
5. U.S. Transthyretin Amyloidosis Treatment Market, By Disease Type, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Hereditary Transthyretin Amyloidosis
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
o Wild Type Amyloidosis
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
6. U.S. Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Hospital Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Online Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
7. Competitive Landscape
o Company Profiles
o Alnylam Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Pfizer, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Prothena Corporation Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o GlaxoSmithKline Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Ionis Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Eidos Therapeutics
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o SOM Innovation Biotech, S.L.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
8. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 22 market data tables and 25 figures on "Transthyretin Amyloidosis Treatment Market - U.S. forecast to 2026".
Request Discount 
Inquire Before Buy
